I. Introduction
The regulation of genetically modified organisms (GMOs) and the debate on the role of biotechnology continue to be highly polarised in Europe and beyond. GMOs can be defined as organisms, with the exception of human beings, in which the genetic material has been altered in a way that does not occur naturally by mating and/or natural recombination.
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Although genetic modification technology was first applied in the 1970s, it was only in the 90s that the first genetically modified (GM) crops were commercialised for food use. At the same time, the EU, in the early 1990s, started developing legislation to regulate the use of GMOs. Whilst other medical or environmental applications of biotechnology are widely accepted, agricultural applications remain highly controversial.
The complexity of the technology, the lack of data about the long-term effects of a relatively new field of application and, notably, a special sensitivity as regards food policies in Europe following repeated food scares, have influenced the opposing views in the debate. In addition, ethical and socio economic concerns play a key role in the GMO debate, contributing to a decline in the public's trust in scientific knowledge as a guide for policy decision-making.
In this context, the EU undertook a comprehensive review of its regulatory framework between 1997 and 2003 in order to improve and strengthen its provisions. This article presents an outline of the review of the EU regulatory framework and of the main provisions of Directive 2001/18/EC on the deliberate release into the environment of GMOs, focusing on their placing on the market.
II. Policy context: the revision of the EU regulatory framework
The EU has been legislating on the authorisation and use of GMOs since the early 1990s, when it adopted the first directives on the contained use of * Paula Rey García, European Commission, DG Environment. The views expressed in this article are personal to the author and do not necessarily reflect those of the European Commission or of DG Environment. The cornerstone of this initial regulatory framework was Directive 90/220/EEC, which has been applicable since October 1991. Under this Directive, eighteen authorisations were granted for the commercial release of GMOs in the EU, for uses including cultivation, import and processing as well as feed and food.
5 Prior to the entry into force of the Regulation on Novel Foods, one GM soy and one GM maize variety had been approved for use in food products under Directive 90/220/EEC. In addition, there was no Community legislation governing feed derived from GMOs before the introduction of Regulation 1829/2003.
6 As a result, eight GMOs for use in feed, mostly maize and rape varieties and one soya variety, were authorised under Directive 90/220/EEC. No consent was granted under this Directive since October 1998 when the last product was authorised. In order to strengthen its existing regulatory framework, the EU started a revision of both its horizontal and its sectoral legislation on GMOs in 1997. In parallel, various food scares (e.g. BSE) eroded the public's faith in governments' abilities to protect consumer and environmental interests in Europe.
7 In this context, the revision of the regulatory framework was also aimed at addressing the loss of public trust in the regulation of the use of GMOs. In February 1998, the Commission presented its legislative proposal for the revision of Directive 90/220/EEC, subject to the co-decision procedure (Article 251 of the EC Treaty). The main objectives were to extend and clarify the scope of the Deliberate Release Directive, to improve the administrative procedures and their efficiency and to introduce common principles of risk assessment.
The proposal took into account the experience gained in the implementation of Directive 90/220/EEC, which was analysed in a Commission report of 1996.
8 Accordingly, it introduced a number of elements such as mandatory monitoring after the placing on the market, differentiated administrative procedures and the obligation to formally consult a Scientific Committee when considering the placing on the market of GMOs. The introduction of common principles of risk assessment, combined with the consultation of a Scientific Committee, was intended to separate the responsibility for risk assessment from the responsibility for risk management decisions.
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In order to strengthen the role of the Member States in the decision-making process, the proposal included the application of the Regulatory Committee procedure, 10 giving the Council the possibility to reject a Commission decision on authorisation by a simple majority. The Commission also proposed to introduce further and detailed labelling requirements, complemented by traceability provisions. The Commission's legislative proposal envisaged greater transparency in the authorisation process by making available to the public the content of the notification, the assessment reports and the opinion of the scientific committees in relation to the placing on the market of GMOs as or in products.
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The Environment Council, at its meeting in June 1999, 12 reached political agreement on a common position on the aforementioned proposal to amend Directive 90/220/EEC -with abstentions by France, In their declaration, the five delegations asked for a tighter and more transparent framework, in particular for risk assessment, in order to restore public and market confidence. They also asked for draft rules on traceability and labelling to be adopted in order to re-start the authorisation process. In February 2001, the five countries, now joined by Austria, re-stated their intention to continue with the standstill concerning new authorisations, pending the adoption of provisions on traceability, labelling and environmental liability. 13 The need for precise rules on traceability and labelling before re-starting the authorisation process was again reiterated at the Environment Council meeting of October 2001. Directive 2001/18/EC introduced a number of innovations when compared with its predecessor Directive 90/220/EEC, in order to clarify and tighten the authorisation procedure. Principles and criteria to be considered when performing an environmental risk assessment, which is a fundamental part of the application for a GMO release, were set out in the Directive.
The Directive has made the consultation of the Scientific Committee(s) and the provision of information to the public mandatory. Post-market monitoring requirements were also introduced, including of the long-term effects associated with the interaction with other GMOs and the environment. Contrary to the initial Commission proposal, the Council can only reject a Commission decision for authorisation by qualified majority.
The revised Deliberate Release Directive introduced general provisions on traceability and labelling, but did not include rules on environmental liability. The Commission presented a proposal on traceability and labelling of GMOs on 25 July 2001, leading to its final adoption in September 2003.
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Last but not least, the Directive on environmental liability, which also covers damage caused by GMOs, was finally adopted in 2004. deliberately released into the environment, including for placing on the market as or in products. This objective is to be pursued in accordance with the precautionary principle.
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III. EU regulatoty framework for GMOs
23
Even though the previous Directive 90/220/EEC made no specific reference to the precautionary principle, its application in implementing this Directive was acknowledged by the European Court of Justice (ECJ) in March 2000. 24 The ECJ stated that the principle had been incorporated in the various steps of the authorisation procedure, notably in the case-by-case assessment prior to a release, as well as in the safeguard clause. Directive 2001/18/EC explicitly incorporates the precautionary principle, going one step further than the previous Directive. The precautionary principle is now a central element of the Directive, which notes in its recital eight that the principle was taken into account during the drafting and 'must be taken into account when implementing it'.
The scope of application of the Directive excludes the transport of genetically modified organisms by rail, road, inland waterway, sea or air, which is governed by the relevant transport legislation. Organisms that have been genetically modified through techniques listed in Annex IB are also exempted from the application of the Directive in accordance with its Article 3.
The The Directive provides for the introduction of GMOs into the environment to be carried out according to the 'step by step' principle. This means that the containment of a GMO is gradually reduced and the scale of the release increased, step by step, but only if the evaluation of the earlier steps in terms of the protection of human health and the environment indicates that the next step can be taken. According to the definitions in Article 2, the deliberate release of a GMO into the environment means its intentional introduction without any specific containment measure to limit the contact between the GMO or combination of GMOs and the population or environment in general. Experimental releases of GMOs for the purposes of research and development of novel varieties are subject to the provisions of Part B of the Directive.
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After studying the behaviour and interactions of the GMO with other organisms and the environment, the company may decide to place the GMO on the market, i.e. make it available to third parties, either in return for payment or free of charge. The GMO may be placed on the market for purposes of importation, cultivation or transformation into different products. The provisions of Part C of the Directive 28 govern the placing on the market of a GMO. GMOs may only be deliberately released or placed on the market in conformity with Part B or Part C, respectively. Notably, the revised Directive introduces a general obligation to gradually phase out Antibiotic Resistant Marker (ARM) genes from GMOs, in line with differentiated timetables for commercial and experimental releases.
29 Genes expressing resistance to antibiotics in use for medical or veterinary treatment, which may have adverse effects on human health and the environment, have to be phased out by 31 December 2004 in GMOs to be placed on the market and by December 2008 for GMOs authorised under Part B. The first stage in the authorisation procedure is the submission of a notification by the interested party or notifier to the relevant competent national authority. A person or company applying for the deliberate release of a GMO or combination of GMOs into the environment for experimental purposes, must submit a notification to the competent national authority of the Member State where the experimental release is to take place. This authority subsequently plays a central role in the decisionmaking process under Part B.
The notification should contain a technical dossier including a full environmental risk assessment as well as a monitoring plan and appropriate safety measures.
30 The decision-making process takes place through a national procedure, where the competent national authority has exclusive responsibility for granting the authorisation. Nevertheless, the other Member States may present observations through the Commission or directly. The eventual authorisation of an experimental release is only valid in the Member State where the notification was submitted. The notifier may proceed with the release only when he has received the written consent of the competent authority and must act in conformity with any conditions required in this consent.
Part B of the Directive provides for differentiated procedures with shorter timetables for the approval of releases of certain GMOs. These procedures have to be applied -subject to certain criteria being met -when sufficient experience has been obtained of releasing specific GMOs in certain ecosystems.
Public consultation on all proposed releases of GMOs, whether for experimental or commercial purposes, is a mandatory requirement under the Directive. For Part B releases, Article 9 requires Member States to consult the public and, where appropriate, interested groups, on the proposed deliberate release. The Directive only states that arrangements for this consultation are to be laid down at national level, leaving the definition of the specific arrangements to the Member States in line with the subsidiarity principle. tion for a commercial release is valid for the whole of the Community territory, in order to ensure compliance with the principle of the free movement of goods. Accordingly, the decision-making process involves all Member States. The first step in the authorisation starts with the notification procedure to the relevant competent authority, which in this case will be the competent authority of the Member State where the GMO is to be placed on the market for the first time. The notification must comprise a dossier of information on the GMO, the receiving environment, interactions between the GMO and the environment, as well as the conditions of release and monitoring, control, waste treatment and emergency control plans. This detailed dossier must include the results of research and development releases concerning the impact on human health and the environment.
32 The notification must also include an environmental risk assessment, 33 carried out by the notifier. The environmental risk assessment should identify and evaluate any potential adverse effects of the GMO. In contrast with the former Deliberate Release Directive, Directive 2001/18/EC sets out the methodological basis for carrying out the environmental risk assessment including its objective, elements to be considered and general principles and methodology to be followed.
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The assessment should not only address the possible direct and immediate effects of releasing the GMO, but also any indirect and delayed effects on human health and the environment, as well as cumulative long term effects. The evaluation of potential adverse effects will examine the characteristics of the GMO, its potential allergenic or toxic effects and the possibility of gene transfer (e.g. of antibiotic resistance genes).
The national authority receiving the notification will examine it for compliance with the requirements of the Directive and prepare an assessment report 35 to be sent to the notifer, indicating its opinion on the placing on the market of the GMO(s) in question. In the event of an unfavourable report, the notification must be rejected, whilst stating the reasons for the refusal. 36 The company may submit a new notification for the same GMO to the competent authority of another Member State, which may eventually issue a different report.
In the event of a favourable assessment regarding the placing on the market of the GMO concerned, the competent authority will inform the other Member States via the European Commission, which will examine the assessment report and may issue observations and objections. In line with the standard procedure as presented in Article 15, in the absence of objections or if outstanding issues are resolved in the conciliation phase, 37 the competent authority that carried out the original assessment may then authorise the placing on the market of the product. The consent for the placing on the market is to be given in writing and for a maximum period of ten years. If at the end of the conciliation phase the objections raised by a competent authority or the Commission are maintained, the Community procedure 38 involving all competent authorities is to be applied for adopting a decision. The European Food Safety Authority (EFSA) 39 has to be consulted for an opinion on the objection(s) as regards the risks of GMOs to human health or to the environment.
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In line with this opinion, the Commission will then prepare a draft decision. A regulatory committee composed of the representatives of the Member States and chaired by the representative of the European Commission would assist the Commission according to the provisions of Article 30(2). This inter-institutional procedure is laid down in Decision 1999/468/EC and provides for the adoption of the decision by the Commission when the Committee gives a favourable opinion by qualified majority. If the draft decision is not in accordance with the opinion of the Committee or if no opinion is delivered, the Commission must submit to the Council a proposal relating to the measures to be taken and inform the European Parliament. The Council of Ministers can adopt or reject the decision by qualified majority.
42
If the Council does not act within three months, the Commission shall adopt the decision though.
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If the Council rejects the proposal by qualified majority, the Commission has the obligation to reexamine it. In this case, the Commission has three options, namely to submit an amended proposal to the Council, re-submit the same proposal or present a legislative proposal through the co-decision procedure, on the basis of the Treaty.
Where a favourable decision has been taken, the competent authority that had prepared the assessment report must give consent in writing to the placing on the market. The notifier may proceed with the placing on the market of the product only after the written consent has been received and in conformity with any conditions set out in that authorisation. Directive 2001/18/EC includes provisions for the renewal of consents, according to certain criteria.
The Community-wide approach applied to decision making under Part C involves all Member States in making an authorising decision. Every Member State is given the opportunity to prevent an authorisation for placing on the market, although subject to the control of the Community institutions. The national authority to which the initial notification was submitted plays a less important role in the decision-making process than in Part B releases. Nevertheless, this competent authority retains a significant degree of discretion in the initial stage of the process and a more marginal one at its end, 44 optimising collaboration between the various competent national authorities.
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After a GMO has been placed on the market, Article 20 of the Directive introduces monitoring requirements in order to trace and identify any direct or indirect, immediate, delayed or unforeseen effects on human health or the environment. A monitoring plan needs to be submitted as part of the application and be implemented in accordance with the consent. A report on the results of the monitoring must also be provided as part of the consent renewal procedure.
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Notably, the Directive introduced the requirement that GMOs placed on the market as or in products must be labelled with a statement that 'this product contains genetically modified organisms'. For products where adventitious or technically unavoidable traces of authorised GMOs cannot be excluded, a minimum threshold may be estab- The Directive tightens the safeguard clause in Article 23, as compared with the former Directive, allowing for limited discretion. A Member State may provisionally restrict or prohibit the use or sale of a GMO on its territory if there is new or additional information affecting the environmental risk assessment on the basis of new scientific knowledge after the consent has been given. Accordingly, the Member State would have to have detailed grounds to consider an authorised GMO to pose a risk to human health or the environment.
Part C of the Directive also introduces mandatory consultation of the public. During the notification process, the public should be informed and have access to the summary notification format, the assessment reports of the competent authorities and the opinions of EFSA. The public can provide comments concerning the summary notification and the assessment report.
Supplementary legislation
Over the past few years, the EU has adopted a number of implementing measures to support the opera- 44 See ECJ, Case C-6/99, supra note 20, where the Court of Justice affirmed that the Competent Authority having issued a favourable assessment report to the Commission must issue the consent in writing, allowing the product to be placed on the market. This may not be the case if new information on risks of the specific GMO to human health and the environment becomes available. Since April 2001, when the Directive entered into force, the Commission has convened regular meetings with the competent authorities (CAs) of the Member States, normally twice a year, in order to exchange views on specific implementation issues. Working groups were established for the purpose of developing the content of the various implementing measures that have been adopted by either the Commission or the Council in the framework of the Directive.
Additional working groups of CAs, under the chairmanship of the European Commission, have been established to address specific issues related to the implementation of the Directive.
56 These groups have focused on specific issues such as post-market monitoring, herbicide tolerance, antibiotic resistance marker genes or access to and exchange of information. Moreover, CAs use these meetings to arrive at a common understanding on the implementation of specific articles of the Directive, thus contributing to harmonising its operation across the EU. The scope of some of the pending applications is restricted to import and processing uses whilst others also include cultivation as a requested use. Although Part C covers all commercial releases, applications for the placing on the market of GMOs for uses including food and/or feed may be filed for authorisation under Regulation 1829/2003 in line with its 'one door, one key' principle. Hence, as a consequence of this evolving legislative framework, the number of applications under Part C of the Directive has been reduced.
The approval of GMOs for cultivation raises concerns as regards the implementation of coexistence measures and the definition of seed thresholds. Due to the labelling requirements, pollen flow between GM and conventional crops may have economic implications for traditional farmers. In accordance with the subsidiarity principle, the Commission adopted a general framework for the development of national strategies on coexistence in 2003, leaving to Member States the definition and implementation of the necessary management measures.
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National approaches to co-existence need to be based on efficient and cost-effective technical guidelines and be fine-tuned to their objective. However, a number of Member States have found the Commission Recommendation on co-existence insufficient and demanded more precise guidelines or legislation. Moreover, several national co-existence measures have been refused by the Commission as disproportionate to their objective and representing a potential barrier to free circulation of authorised GMOs.
Also, in connection with cultivation, thresholds below which adventitious traces of authorised GM seeds in conventional lots do not require labelling still need to be established by the European Commission. Scientific and political consensus in connection with the level of these thresholds seems difficult to attain.
The implementation of the revised regulatory framework has not prevented various environmental and safety concerns to remain, which has led various Member States to invoke the safeguard clause. In relation to Directive 90/220/EEC, the safeguard clause was invoked on nine separate occasions, eight of which were maintained under Article 23 of Directive 2001/18/EC.
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In addition, Hungary invoked the safeguard clause in January 2005 in order to prohibit the cultivation of MON 810 on its territory. In June 2005, the Environment Council reached qualified majority against eight proposals to lift the existing bans. As a result, EFSA has been consulted to obtain an updated opinion and the Commission needs to consider whether to submit the same or amended proposals back to the Council or to prepare proposals for adoption through co-decision.
Some Member States have questioned the decision-making process under Part C, considering that final decisions may go against a majority of them. The division of opinions amongst Member States, often polarised either in favour of or against the technology, is leading to the application of the Community procedure to every Part C notification. The subsequent absence of the necessary majority at Council level makes it necessary to send authorisations back to the Commission for adoption.
A Commission report on the implementation and operation of the Directive, according to provisions in its Article 31, is due in 2006. This report will allow the identification of specific areas in the operation of the Directive, where further guidance may be necessary. Moreover, and according to the provisions of the Directive, the Commission will assess the feasibility of various options to further improve the consistency and efficiency of the regulatory framework on GMOs, including a centralised Community authorisation procedure and the arrangements for the final decision making by the Commission.
V. Conclusion
The comprehensive review of the EU regulatory framework for GMOs has addressed the various concerns that had triggered it. As a result, and in As a result of the introduction of mandatory consultation of EFSA and the establishment of common principles for undertaking environmental risk assessments, the scientific basis for undertaking risk assessments was strengthened, whilst the expert assessment has been separated from the risk management process leading to decisions on GMOs authorisations.
The implementation phase of the regulatory framework will define its performance in practice. Taking into account that the Directive provides for a case-by-case analysis of GMOs and introduces a number of discretionary elements in the decisionmaking process, the implementation phase may allow for the fine-tuning of the policy. Furthermore, guidance on specific issues is being developed as part of the ongoing operation of the Directive.
Experience so far shows that the Directive, together with the revised wider regulatory framework, has addressed fundamental concerns that should help increase confidence in the legislative framework. Outstanding regulatory issues such as its correct transposition, addressing safeguard clauses and the definition of seed thresholds need further action.
However, decision making under the Directive continues to be very problematic and the resulting decisions have been highly contested. The implementation of the revised regulatory framework has not, so far, removed some of the existing environmental and safety objections and the review has not satisfied public concerns related to ethical and socio-economic considerations, which not only concern the regulatory framework for GMOs but the technology as such.
The ongoing analysis of the implementation of Directive 2001/18/EC and of the complete regulatory framework on GMOs will help to identify areas where additional guidance is necessary. Further improvement to the efficiency of the regulatory framework will also need to be assessed. Nevertheless, in order to address the broader concerns, a wider debate on the role of biotechnology and on how to mainstream its application in line with societal concerns is going to be necessary. 
